ClinicalTrials.gg
CompletedNCT00591266Updated Jul 22, 2011Results posted

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

A Phase 3 interventional study of Azilsartan Medoxomil and amlodipine and Azilsartan Medoxomil and amlodipine in Hypertension, sponsored by Takeda. Completed at 50 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-22.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
566
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.

Enrollment
11th of 21
566 · median 566
Started
2007
with 6 others
Phase 3
17 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
19 of 21
Takeda

Among the 21 studies testing azilsartan medoxomil in Hypertension, this one is the 11th largest by enrollment, is one of 7 that started in 2007, is one of 17 in phase 3, and was the 2nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing azilsartan medoxomil in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine alone.

Read the detailed description

Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure. Despite the availability of antihypertensive treatments, hypertension remains inadequately controlled; only about one third of patients continue to maintain control successfully.

A major component of blood pressure regulation is the renin-angiotensin-aldosterone system, a system of hormone-mediated feedback interactions that results in the relaxation or constriction of blood vessels in response to various stimuli. Angiotensin II, a polypeptide hormone, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme as part of the renin-angiotensin-aldosterone system. Angiotensin II is the principal pressor agent of the renin-angiotensin-aldosterone system with a myriad of effects on the cardiovascular system and on electrolyte homeostasis.

Takeda Global Research \& Development Center, Inc. is developing TAK-491 (azilsartan medoxomil) to treat patients with essential hypertension. Azilsartan medoxomil is a prodrug that is hydrolyzed to the active moiety, azilsartan, which is a selective antagonist of the angiotensin II type 1 receptor subtype.

Amlodipine is a slow-channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.

This study is being conducted to determine whether administration of azilsartan medoxomil in combination with amlodipine in participants with uncontrolled hypertension is more efficacious in reducing systolic blood pressure than amlodipine alone. Participation in this study is anticipated to be approximately 10 weeks.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Blood pressure
  • blood pressure monitoring ambulatory
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has essential hypertension and 24-hour mean systolic blood pressure greater than or equal to 140 mm Hg and less than or equal to 180 mm Hg.
  2. Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study
  3. Has clinical laboratory evaluations within the reference range for the testing laboratory or the results are deemed not for inclusion into this study by the investigator.
  4. Is willing to discontinue current antihypertensive medications.

Exclusion criteria

Exclusion Criteria:

  1. Has sitting trough clinic diastolic blood pressure greater than 119 mm Hg.
  2. Has a baseline 24 hour ambulatory blood pressure monitoring reading of insufficient quality.
  3. The subject is hypersensitive to angiotensin II receptor blockers or calcium channel blockers.
  4. Has a recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  5. Has cardiac conduction defects.
  6. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  7. Has secondary hypertension of any etiology
  8. Is non-compliant with study medication during placebo run-in period.
  9. Has severe renal dysfunction or disease.
  10. Has known or suspected unilateral or bilateral renal artery stenosis.
  11. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.
  12. Has a previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.
  13. Has type 1 or poorly controlled type 2 diabetes mellitus.
  14. Has hyperkalemia as defined by the central laboratory normal reference range,
  15. Has an level of greater than 2.5 times the , active liver disease or jaundice.
  16. Has an upper arm circumference less than 24 cm or greater than 42 cm.
  17. Works night (3rd) shift.
  18. Currently participating in another study or has participated in an investigational study within 30 days prior to randomization.
  19. Has any other serious disease or condition that would compromise subject safety or make it difficult to successfully manage and follow the subject according to the protocol.
  20. Has been randomized in a previous TAK-491 study.
  21. Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
566 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil 40 mg QD and Amlodipine 5 mg QD

    Drug: Azilsartan Medoxomil and amlodipine

  • Experimental
    Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD

    Drug: Azilsartan Medoxomil and amlodipine

  • Active comparator
    Amlodipine 5 mg QD

    Drug: Amlodipine

Interventions

  • DrugAzilsartan Medoxomil and amlodipine

    Drug pages: Azilsartan medoxomil · Amlodipine

    Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.

    Also known as: Norvasc, TAK-491, Edarbi

  • DrugAzilsartan Medoxomil and amlodipine

    Drug pages: Azilsartan medoxomil · Amlodipine

    Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.

    Also known as: Norvasc, TAK-491, Edarbi

  • Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.

    Also known as: Norvasc

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 6.

Secondary outcomes

  1. Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

    The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  2. Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 6.

  3. Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

    The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  4. Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 6.

  5. Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 6.

  6. Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 6.

  7. Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 6.

  8. Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

    The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 6.

  9. Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

    The change in the 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

    Time frame: Baseline and Week 6.

  10. Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 6.

  11. Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 6.

  12. Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

    Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6 relative to baseline, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  13. Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

    Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6 relative to baseline, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of 3 trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 6.

  14. Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response

    Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6 relative to baseline, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.

    Time frame: Baseline and Week 6.

07

Results

Posted Apr 19, 2011

Participant flow

Participants enrolled at 65 investigative sites in Argentina, Chile, Mexico, Peru and the United States from 03 October 2007 to 03 April 2009.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Started189188189
Completed180177175
Not completed91114
Withdrew: Adverse event223
Withdrew: Lost to follow-up010
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject625
Withdrew: Lack of efficacy020
Withdrew: Other145

Outcome measures

PrimaryChange From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-24.79 ± 0.757-24.51 ± 0.754-13.60 ± 0.754
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.) · Mean difference (final values): -11.19 · 95% CI -13.29 to -9.09
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.) · Mean difference (final values): -10.91 · 95% CI -13.00 to -8.81
SecondaryChange From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.-26.96 ± 1.037-25.50 ± 1.048-15.94 ± 1.060
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.) · Mean difference (final values): -11.02 · 95% CI -13.93 to -8.10
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented. Overall 0.05 level of significance for multiple comparisons controlled using closed testing procedure.) · Mean difference (final values): -9.56 · 95% CI -12.48 to -6.63
SecondaryChange From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-15.26 ± 0.492-15.43 ± 0.490-7.79 ± 0.490
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.48 · 95% CI -8.84 to -6.11
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.65 · 95% CI -9.01 to -6.28
SecondaryChange From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure-12.00 ± 0.602-12.65 ± 0.609-7.07 ± 0.616
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -4.93 · 95% CI -6.62 to -3.23
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.58 · 95% CI -7.28 to -3.88
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-25.42 ± 0.802-24.95 ± 0.800-13.79 ± 0.799
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.64 · 95% CI -13.86 to -9.41
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.17 · 95% CI -13.39 to -8.95
SecondaryChange From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-15.81 ± 0.535-15.86 ± 0.533-7.82 ± 0.533
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -7.99 · 95% CI -9.47 to -6.50
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.04 · 95% CI -9.52 to -6.55
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-22.75 ± 0.853-22.72 ± 0.849-13.05 ± 0.848
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.70 · 95% CI -12.07 to -7.34
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -9.67 · 95% CI -12.03 to -7.31
SecondaryChange From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-13.76 ± 0.606-13.78 ± 0.604-7.50 ± 0.604
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.26 · 95% CI -7.94 to -4.57
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.28 · 95% CI -7.96 to -4.60
SecondaryChange From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring-26.10 ± 0.850-25.40 ± 0.847-13.82 ± 0.846
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -12.27 · 95% CI -14.63 to -9.92
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -11.58 · 95% CI -13.93 to -9.23
SecondaryChange From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring-16.13 ± 0.575-15.97 ± 0.574-7.74 ± 0.574
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.39 · 95% CI -9.98 to -6.79
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.23 · 95% CI -9.82 to -6.64
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-22.60 ± 0.942-22.67 ± 0.938-13.76 ± 0.938
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.83 · 95% CI -11.45 to -6.22
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -8.91 · 95% CI -11.51 to -6.30
SecondaryChange From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 6.
Reported as:
Least squares mean · mmHg
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.-14.34 ± 0.698-14.93 ± 0.696-8.39 ± 0.696
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -5.94 · 95% CI -7.88 to -4.00
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Unadjusted p-value is presented.) · Mean difference (final values): -6.54 · 95% CI -8.47 to -4.61
SecondaryPercentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6 relative to baseline, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
percentage of participantsAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg72.771.645.8
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · Regression, Logistic · p = <0.001 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 3.37 · 95% CI 2.15 to 5.26
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · Regression, Logistic · p = <0.001 (P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 3.21 · 95% CI 2.05 to 5.03
SecondaryPercentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6 relative to baseline, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of 3 trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
percentage of participantsAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg86.187.465.9
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · Regression, Logistic · p = <0.001 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 3.54 · 95% CI 2.08 to 6.02
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · Regression, Logistic · p = <0.001 (P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 3.90 · 95% CI 2.25 to 6.75
SecondaryPercentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response

Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6 relative to baseline, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.

Time frame:
Baseline and Week 6.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
percentage of participantsAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response65.869.443.0
Statistical analysis
  • Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD vs Amlodipine 5 mg QD · Regression, Logistic · p = <0.001 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 2.62 · 95% CI 1.71 to 4.02
  • Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD vs Amlodipine 5 mg QD · Regression, Logistic · p = <0.001 (P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value is presented.) · Odds ratio (or): 3.12 · 95% CI 2.01 to 4.82

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QD—1/190 (0.5%)11/190 (5.8%)
Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD—2/188 (1.1%)10/188 (5.3%)
Amlodipine 5 mg QD—1/185 (0.5%)10/185 (5.4%)
Most frequent serious events
Most frequent serious events
EventAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
Chest painGeneral disorders0/1900/1881/185
Urinary tract infectionInfections and infestations0/1901/1880/185
Ovarian cyst torsionReproductive system and breast disorders0/1901/1880/185
SyncopeNervous system disorders1/1900/1880/185
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QD
HeadacheNervous system disorders11/19010/18810/185

Baseline characteristics

Age Categorical
Age Categorical(participants)Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QDTotal
<45 years28231566
Between 45 and 64 years97111115323
≥65 years645459177
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil 40 mg QD Amlodipine 5 mg QDAzilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QDAmlodipine 5 mg QDTotal
Female998595279
Male9010394287
08

Study locations

50 sites
  • Mesa, Arizona, United States
  • Phoenix, Arizona, United States
  • Anaheim, California, United States
  • Beverly Hills, California, United States
  • Burbank, California, United States
  • Burlingame, California, United States
  • La Jolla, California, United States
  • Orange, California, United States
  • Roseville, California, United States
  • Tustin, California, United States
  • Wheat Ridge, Colorado, United States
  • Newark, Delaware, United States
  • Washington, District of Columbia, United States
  • Hialeah, Florida, United States
  • Longwood, Florida, United States
  • Tampa, Florida, United States
  • Honolulu, Hawaii, United States
  • Boise, Idaho, United States
  • Chicago, Illinois, United States
  • Gurnee, Illinois, United States
  • Peoria, Illinois, United States
  • Elkhart, Indiana, United States
  • Crestview Hills, Kentucky, United States
  • Lexington, Kentucky, United States
  • Riverdale, Maryland, United States
  • Brockton, Massachusetts, United States
  • Haverhill, Massachusetts, United States
  • North Dartmouth, Massachusetts, United States
  • Kansas City, Missouri, United States
  • Omaha, Nebraska, United States
  • Raleigh, North Carolina, United States
  • Akron, Ohio, United States
  • Canton, Ohio, United States
  • Cincinnati, Ohio, United States
  • Mogadore, Ohio, United States
  • Norman, Oklahoma, United States
  • Tulsa, Oklahoma, United States
  • Warminster, Pennsylvania, United States
  • Cumberland, Rhode Island, United States
  • Arlington, Texas, United States
  • Austin, Texas, United States
  • Carrollton, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Irvine, Texas, United States
  • Lake Jackson, Texas, United States
  • North Richland Hills, Texas, United States
  • Manassas, Virginia, United States
  • Renton, Washington, United States
  • Menomonee Falls, Wisconsin, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Mar 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2007
First posted
Jan 11, 2008
Start
Oct 2007
Primary completionActual
Mar 2009
CompletionActual
Apr 2009
Results first posted
Apr 19, 2011
Last update
Jul 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00591266
Lead sponsor
Takeda
First posted
Jan 11, 2008
Start date
Oct 2007
Primary completion
Mar 2009
Completion
Apr 2009
Results posted
Apr 19, 2011
Last update
Jul 22, 2011

Study contacts

Executive Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azilsartan medoxomil · Amlodipine

Start the discussion